A Prospective Observational Cohort Study to Monitor and Compare the Occurrence of Hypersensitivity Reaction and Hepatotoxicity in Patients Receiving Dolutegravir (with and without Abacavir) or other Integrase Inhibitors (with or without Abacavir) (201177)

First published 08/10/2014

Last updated 23/04/2024

EU PAS number:

EUPAS7597

Study

Finalised

Documents

Study protocol

Initial protocol

201177-protocol-redact

English (554.73 KB - PDF)View document

Updated protocol

viiv-201177-protocol1-redact

First published: 22/02/2024

English (85.82 KB - PDF)View document

Study results

viiv-201177-clinical-study-report-final-redact

English (1.94 MB - PDF)View document

Study report

viiv-201177-clinical-study-report-redact

English (1.49 MB - PDF)View document

viiv-201177-clinical-study-report-redact-v02

English (1.04 MB - PDF)View document

viiv-201177-clinical-study-report1-redact

English (1.31 MB - PDF)View document

Other information

Study, other information

viiv-201177-clinical-study-report-redact-v02.pdf

English (1.04 MB - PDF)View document

viiv-201177-clinical-study-report1-redact.pdf

English (1.31 MB - PDF)View document

ENCePP Seal

ENCePP Seal documents

Secondary tabs